You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

366 Results
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
EPIrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
In October 2024, the Ontario Breast Screening Program lowered the starting age for screening from age 50 to age 40.This page provides breast cancer...
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
ODB - General Benefit
    bicalutamide
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
leuprolide,
bicalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Drug
Other Name(s): Enhertu®
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2025
Drug
Other Name(s): Adcetris®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025

Pages